The one-week order reverses Friday’s nationwide ban on online prescribing and mail delivery while the FDA’s review of the abortion pill’s rules continues.
Medication abortion accounts for nearly two-thirds of US terminations, and about a quarter are provided via telehealth, making the case significant in states with bans or heavy restrictions.
Providers had begun shifting toward misoprostol-only abortions, but legal threats to mailed abortion drugs and Louisiana-style controls could still disrupt abortion, miscarriage and obstetric care.
How could the Supreme Court's ruling on one pill redefine the FDA's authority over all approved drugs nationwide?
Can a 19th-century anti-vice law be revived to halt the modern-day mailing of essential medication?
What does this case signal for the future of telemedicine for other sensitive, life-altering medications?
In May 2026, Louisiana challenged the FDA's 2021 policy allowing mifepristone to be prescribed via telehealth and mailed, leading the Fifth Circuit to reinstate in-person dispensing requirements, which disrupted abortion access nationwide. In response, manufacturers filed emergency requests, prompting Justice Alito to issue a temporary stay that restored telehealth and mail access while setting a May 7 deadline for further briefs. This legal battle stems from the 2022 Dobbs decision that returned abortion regulation to states, resulting in restrictive bans that motivated Louisiana's lawsuit. The ongoing uncertainty has already forced providers to scale back telehealth services, highlighting the high stakes for reproductive healthcare access.